Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
about
Drug resistance in influenza A virus: the epidemiology and management.Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design.A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase.
P2860
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Resistance to Mutant Group 2 I ...... ir-Zanamivir Hybrid Inhibitor.
@ast
Resistance to Mutant Group 2 I ...... ir-Zanamivir Hybrid Inhibitor.
@en
type
label
Resistance to Mutant Group 2 I ...... ir-Zanamivir Hybrid Inhibitor.
@ast
Resistance to Mutant Group 2 I ...... ir-Zanamivir Hybrid Inhibitor.
@en
prefLabel
Resistance to Mutant Group 2 I ...... ir-Zanamivir Hybrid Inhibitor.
@ast
Resistance to Mutant Group 2 I ...... ir-Zanamivir Hybrid Inhibitor.
@en
P2093
P2860
P356
P1433
P1476
Resistance to Mutant Group 2 I ...... ir-Zanamivir Hybrid Inhibitor.
@en
P2093
B Mario Pinto
Christopher J Vavricka
Jianxun Qi
Sankar Mohan
Xuebing Li
Yuhang Chen
P2860
P304
10693-10700
P356
10.1128/JVI.01703-16
P577
2016-09-21T00:00:00Z